Candel Therapeutics annual return on equity
2021
2022
2023
2024
2025
Candel Therapeutics Return on Equity (ROE) Growth & History (CADL)
Candel Therapeutics's return on equity was −64.58% for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −64.58% | +74.98 pp |
| 2024 | 2024-12-31 | −139.56% | −14.06 pp |
| 2023 | 2023-12-31 | −125.50% | −91.90 pp |
| 2022 | 2022-12-31 | −33.61% | +144.45 pp |
| 2021 | 2021-12-31 | −178.06% | — |
Candel Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −29.46% | −23.64 pp |
| Q1 2026 | 2026-03-31 | −9.33% | −19.80 pp |
| Q4 2025 | 2025-12-31 | −44.68% | +10.44 pp |
| Q3 2025 | 2025-09-30 | −13.23% | — |
| Q2 2025 | 2025-06-30 | −5.82% | — |
| Q1 2025 | 2025-03-31 | 10.47% | +98.28 pp |
| Q4 2024 | 2024-12-31 | −55.11% | +6.93 pp |
| Q1 2024 | 2024-03-31 | −87.81% | −67.68 pp |
| Q4 2023 | 2023-12-31 | −62.04% | −51.86 pp |
| Q3 2023 | 2023-09-30 | −31.36% | −15.87 pp |
| Q2 2023 | 2023-06-30 | −27.30% | −20.60 pp |
| Q1 2023 | 2023-03-31 | −20.13% | −18.77 pp |
| Q4 2022 | 2022-12-31 | −10.18% | −12.69 pp |
| Q3 2022 | 2022-09-30 | −15.49% | +147.67 pp |
| Q2 2022 | 2022-06-30 | −6.70% | — |
| Q1 2022 | 2022-03-31 | −1.37% | — |
| Q4 2021 | 2021-12-31 | 2.51% | — |
| Q3 2021 | 2021-09-30 | −163.15% | — |
Candel Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Candel Therapeutics's return on equity increased from −178.06% to −64.58%, a change of +113.48 percentage points. The latest reported quarter, Q2 2026, shows −29.46%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Candel Therapeutics source filings ↗